Trevi Therapeutics
Manufacturing · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
195 Church St Fl 14, New Haven, Connecti...Phone Number
(203) 304-2499Website
www.trevitherapeutics.comRevenue
$7.2 MillionStock Symbol
TRVIIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing the investigational therapy Haduvio (oral nalbuphine ER) for patients with difficult to treat chronic cough conditions by targeting the central and peripheral nervous systems. The company was founded in 2011 and is based in New Haven, Connecticut.Explore more
Trevi Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Trevi Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Trevi Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Trevi Therapeutics
Trevi Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Trevi Therapeutics is spiking on competitors!
Click to see if Trevi Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Trevi Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check if Trevi Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Trevi Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Trevi Therapeutics
Compare insights from companies similar to Trevi Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Trevi Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Trevi Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Trevi Therapeutics.
Trevi Therapeutics financials insights
Gather financial insights about Trevi Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$10M
2014
Series B
$26M
2015
Debt
$15M
2017
Series C
$50.5M
2019
Share Placement
$15M
Stock Offering
$55M
2022
Share Placement
$55M
Trevi Therapeutics Tech Stack
A closer look at the technologies used by Trevi Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Events
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Trevi Therapeutics News & Media
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fiTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics to host conference call and webcast today, May 5, on 1Q 2026 financial results and business updatesTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Trevi Therapeutics announces oral presentation and multiple posters accepted for the ATS 2026 International Conference
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Trevi Therapeutics
Sign Up For FreeTo access detailed company insights
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing the investigational therapy Haduvio (oral nalbuphine ER) for patients with difficult to treat chronic cough conditions by targeting the central and peripheral nervous systems. The company was founded in 2011 and is based in New Haven, Connecticut.... Read More
